These conditions increase the number of challenged CFSs harboring FANCD2 in G2/M (23) and are typically used to study the mechanisms and proteins that resolve CFS aberrations (21,23,37,38). The gene discussed is FANCD2; the disease is myalgic encephalomeyelitis/chronic fatigue syndrome.